SAN ANTONIO, Dec. 20, 2017 /PRNewswire/ -- Dr. Louis Fernand Fabre, MD, Ph.D., is recognized by Continental Who's Who as a Pinnacle Professional Member in the fields of Psychiatry and Mental Health in recognition of his role as the developer of most of the drugs used in modern psychopharmacology.
Over the 1970's, 80's and 90's Dr. Fabre was involved in the clinical development of at least 29 drugs. Twenty-six of the 29 drugs were approved somewhere in the world (90%) with 55% approved in the United States. For most of these drugs Dr. Fabre did the pivotal trials which resulted in approval. Dr. Fabre was often involved in the first study in man. He often found the dose and regimen and the side effect profile of the drug. He did Phase 1 through Phase 4 studies. Some of the drugs are: Prozac, Paxil, Zoloft, Desyrel, Effexor, Xanax, Halcion, Wellbutrin, Seroquel, Celexa, and Ascendin. For some of these drugs he wrote the protocols and even collaborated in the clinical development plan. Currently he is working on an antidepressant drug that increases rather than decreases sexual function.
Dr. Fabre believes to be an expert in this field one must: do clinical trials, interact with the FDA, write scientific papers, give lectures, and treat patients. He has carried out 500 clinical trials, written close to 200 scientific papers, and given over 1000 lectures.
Dr. Fabre takes a dim view of so called experts that haven't' seen a patient in 20 years. Now he sees approximately 30 patients a day at the Alamo Mental Health Group in San Antonio Texas. A private mental health organization that serves as a full-service psychiatric clinic. The philosophy is to provide timely services that are both effective and efficient for children, adolescents, adults, and geriatrics.
Amassing over forty years of experience in the field of Psychiatry, Dr. Fabre is a prominent figure in the mental health industry and known as the Father of Modern Psychopharmacology. Throughout his career, Dr. Fabre has specialized in the areas of mood, anxiety, and psychotic disorders, as well as child and adolescent disorders, and substance abuse disorders.
Heavily involved in the development of various pharmaceuticals, Dr. Fabre has played a large part in launching numerous brands of psychiatric medications. "I wrote the protocols for Prozac," he says. "I convinced a very skeptical pharmaceutical company that Prozac would be the best anti-depressant on the market. Of course, I was right. It sold five Billion dollars a year at its peak."
Throughout the course of his education and training, Dr. Fabre obtained his Doctor of Philosophy degree in Physiology from Case Western Reserve University in 1966 and attained his medical degree from Baylor College of Medicine in 1969. He went on to complete an Internship and Residency through the Baylor Affiliated Hospitals. He is Board Certified by the American Board of Psychiatry and Neurology. In his early career he held several positions at the Texas Research Institute of Mental Science (TRIMS) including Director of Alcohol Research and Treatment for the State of Texas, and Assistant Director of TRIMS. In 1992 Dr. Fabre co-founded Fabre-Kramer Pharmaceuticals, Inc. where he continues as Chairman of the Board of Directors.
For more information, you can visit: www.alamomentalhealth.com
Contact: Katherine Green, 516-825-5634, email@example.com
SOURCE Continental Who's Who